Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/ASO.2004.03.057
Annals of Surgical Oncology 11:21-26 (2004)
© 2004 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saha, S.
Right arrow Articles by Mannam, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saha, S.
Right arrow Articles by Mannam, S.
Related Collections
Right arrow Other Colorectal

ORIGINAL ARTICLES

Lymphazurin 1% Versus 99mTc Sulfur Colloid for Lymphatic Mapping in Colorectal Tumors: A Comparative Analysis

Sukamal Saha, MD, Adrian G. Dan, MD, Blake Berman, MD, David Wiese, MD, Elie Schochet, MD, Kimberly Barber, PhD, Sharan Choudhri, MD, Sunil Kaushal, MD, Balvant Ganatra, MD, Delip Desai, MD, Marigowda Nagaraju, MD and S. Mannam, MD

From the McLaren Regional Medical Center, Michigan State University Department of Surgery, Flint, Michigan.

Correspondence: Address correspondence and reprint requests to: Sukamal Saha, MD, Department of Surgery, McLaren Regional Medical Center, Michigan State University, 3500 Calkins Road, Suite A, Flint, MI 48532; Fax: 810-230-9607; E-mail: ssahadr{at}aol.com

Background: The combination of isosulfan blue (Lymphazurin) 1% and 99mTc sulfur colloid (TSC) may improve the feasibility and accuracy of lymphatic mapping for colorectal cancer.

Methods: At laparotomy, 1 to 2 mL of isosulfan blue and 1 mCi of TSC were injected subserosally. Sentinel lymph node (SLN) designation was based on blue staining for isosulfan blue and increased radioactivity for TSC. Focused pathologic analysis of the SLNs and standard pathologic examination of the remaining specimen were performed.

Results: A total of 57 consecutive patients were studied (median age, 71 years; 27 men and 30 women). Mapping was successful in 100% of patients with isosulfan blue and in 89% with TSC (P = .47). Lymphatic mapping was accurate in 93% of patients with isosulfan blue versus 92% with TSC (P = .53). The combined accuracy was 95%. A total of 709 lymph nodes were found (12.4 per patient): 553 non-SLNs (5.6% nodal positivity) versus 156 SLNs (16.7% nodal positivity; P < .0001). Isosulfan blue detected 152 SLNs, TSC detected 100, and both modalities detected 96. Of the SLNs detected by isosulfan blue only, 10.7% had nodal metastases, whereas 19.8% of SLNs detected with both modalities had nodal metastases (P = .028). Nodal disease was detected in 41% of patients with invasive carcinoma. Metastases were detected only in the SLNs in 26% and only by micrometastases in 11% of these patients.

Conclusions: These data confirm the efficacy of isosulfan blue and TSC for SLN mapping in colorectal tumors. No significant difference with respect to feasibility or accuracy exists between isosulfan blue and TSC. The metastatic yield is significantly higher in SLNs identified by both modalities compared with isosulfan blue only.

Key Words: Sentinel lymph node • Lymphatic mapping • Colorectal cancer • Technetium • Lymphazurin




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
R. J. de Haas, D. A. Wicherts, M. G. G. Hobbelink, I. H. M. B. Rinkes, M. E. I. Schipper, J.-A. van der Zee, and R. van Hillegersberg
Sentinel Lymph Node Mapping in Colon Cancer: Current Status
Ann. Surg. Oncol., March 1, 2007; 14(3): 1070 - 1080.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
A. G. Dan, S. Saha, K. M. Monson, D. Wiese, E. Schochet, K. R. Barber, B. Ganatra, D. Desai, and S. Kaushal
1% Lymphazurin vs 10% Fluorescein for Sentinel Node Mapping in Colorectal Tumors
Arch Surg, November 1, 2004; 139(11): 1180 - 1184.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society of Surgical Oncology.